Rémi Yaïci,Mathias Roth,Lukas Juergens,Sami Al Nawaiseh,Dick Burkhard,Volker Besgen,Matthias Fuest,Christian Girbardt,Ulrike Hampel,Jens Heichel,Arnd Heiligenhaus,Martina C Herwig-Carl,Vinodh Kakkassery,Kalliopi Kontopoulou,Karin U Löffler,Philip Christian Maier,Bernhard Nölle,Johanna Pach,Sebastian Paul,Uwe Pleyer,Michael Pöllmann,Mark Saeger,Enno Schmidt,Sebastian Siebelmann,Ekatarina Sokolenko,Lisa Strudel,Nicole Stübiger,Melih Tarhan,Johanna Theuersbacher,Christian van Oterendorp,Marten Walker,Carolin Wiecha,Agata Anna Wykrota,Gerd Geerling

Abstract:Background: Ocular involvement in mucous membrane pemphigoid (MMP) is relatively rare, with a prevalence of 25 cases per million population, equating to approx. 2,100 patients throughout Germany. Diagnosis can be difficult - especially in cases of isolated ocular involvement - and treatment can be complex and lengthy. Immunosuppressants or immunomodulatory drugs are often used. Due to the complexity of diagnosis and treatment, MMP patients are usually referred to specialized centers. The aim of this project was to evaluate the current care situation of patients with ocular MMP in Germany. Methods: A paper-based survey was designed and sent to all university eye clinics and other specialized centers in Germany in April 2020. The survey asked about the existence of a specialized outpatient service, the total annual number of patients with MMP, the annual number of newly diagnosed patients, any interdisciplinary collaboration for diagnostic or therapeutic purposes, as well as the local and systemic therapy used. Results: Of a total of 44 clinics, 28 (64%) responded, reporting a total average of 27 ± 42 (0 - 200) patients and 3.6 ± 2.2 (0 - 10) new cases per year. This corresponds to a total of 741 patients. Only nine (32%) of the responding clinics offer specialized MMP clinics. 93% of the centers collaborate with the local dermatology department. 79% perform serological and histological diagnostics in-house. About half of the centers (n = 16) apply a standardized treatment regime. Systemic glucocorticoids (66.7%) are most commonly used, followed by mycophenolate mofetil and dapsone (57.1%), rituximab (33.3%), azathioprine and cyclophosphamide (28.6%), as well as methotrexate (19.0%). The least frequently used treatment is intravenous immunoglobulin (14.3%). Conclusion: This survey of German ophthalmology departments obtained data from about one third of the estimated total cohort of all patients with MMP in Germany. These are presumed to be exclusively patients with at least one ocular involvement. The complex care of these patients is usually provided in collaboration with a dermatologist and with the use of systemic anti-inflammatory medication. Currently, an ophthalmological MMP register is being established to better record the epidemiology and care situation of this rare disease in Germany and to improve it in the long term.

[Local anesthetic effect of several lipid-soluble compounds on the carbamylcholine response of the Electrophorus electroplax and the acetylcholine binding to the cholinergic receptor of Torpedo].

On the Current Care Situation and Treatment of Ocular Mucous Membrane Pemphigoid in Germany

The Role of Serology in the Diagnosis of Ocular Predominant Mucous Membrane Pemphigoid and the Search for an Ocular-Specific Autoantigen

[Initial results of the German ocular pemphigoid register]

Clinical Results of Intraductal Meibomian Gland Probing Combined with Intense Pulsed Light in Treating Patients with Refractory Obstructive Meibomian Gland Dysfunction: a Randomized Controlled Trial

Mucous Membrane Pemphigoid: a Retrospective Study of 68 Cases

Gathering and Analyzing Identity Leaks for Security Awareness

[Mucous membrane pemphigoid: a review]

Longitudinal-Transverse Separations of Structure Functions at Low Q 2 for Hydrogen and Deuterium

Decoding techniques for some specially constructed dc-free codes

A 10-Year Review of the Management of Ocular Mucous Membrane Pemphigoid: A Private Practice Experience

S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid

Oral mucous membrane pemphigoid: updates in diagnosis and management

European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II

Mucous Membrane Pemphigoid: A Case Report with Oral and Ocular Presentation

European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I

Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230

Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study

[Preoperative prevention and therapy of deep venous thromboses of the leg--current trends].

Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid

Diagnosis of oral mucous membrane pemphigoid by means of combined serologic testing